Accenture Capital Inc., a subsidiary of Accenture plc, has announced the pricing of a $5 billion senior notes offering on October 1, 2024. The offering includes four series of notes with varying maturities: $1.1 billion of 3.900% senior notes due 2027, $1.2 billion of 4.050% senior notes due 2029, $1.2 billion of 4.250% senior notes due 2031, and $1.5 billion of 4.500% senior notes due 2034. These notes are to be fully and unconditionally guaranteed by Accenture plc. The trade date for the notes is set for October 1, 2024, with a settlement date of October 4, 2024. The notes have been rated Aa3 by Moody’s, AA- by Standard & Poor’s, and A+ by Fitch, all with a stable outlook. The net proceeds before expenses from the 2027, 2029, 2031, and 2034 notes are approximately $1.095 billion, $1.193 billion, $1.193 billion, and $1.491 billion, respectively. The offering...Show More

Accenture Capital Inc., a subsidiary of Accenture plc, has announced the pricing of a $5 billion senior notes offering on October 1, 2024. The offering includes four series of notes with varying maturities: $1.1 billion of 3.900% senior notes due 2027, $1.2 billion of 4.050% senior notes due 2029, $1.2 billion of 4.250% senior notes due 2031, and $1.5 billion of 4.500% senior notes due 2034. These notes are to be fully and unconditionally guaranteed by Accenture plc. The trade date for the notes is set for October 1, 2024, with a settlement date of October 4, 2024. The notes have been rated Aa3 by Moody’s, AA- by Standard & Poor’s, and A+ by Fitch, all with a stable outlook. The net proceeds before expenses from the 2027, 2029, 2031, and 2034 notes are approximately $1.095 billion, $1.193 billion, $1.193 billion, and $1.491 billion, respectively. The offering was managed by a consortium of banks including J.P. Morgan Securities LLC, BofA Securities, Inc., and Citigroup Global Markets Inc. among others. The issuer has the option to redeem the notes at specified times before maturity at a set redemption price, with the terms detailed in the prospectus supplement filed with the SEC.